Aclaris Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Aclaris Therapeutics, Inc. (ACRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 72.18% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-06
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 72.44%, a 12.98% decline year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-03-31 was 83.25%, a 1.76% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 81.81%, a 5.25% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 77.73%, a 0.28% decline year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 82.79%, a 1.43% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 81.62%, a 5.00% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 77.73%, a 0.28% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 77.95%, a 1.76% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 72.18% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 72.44% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 82.79% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 82.77% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 82.71% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 83.25% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 81.62% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 81.95% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 81.95% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 81.81% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 77.73% 10-K · filed 2025-02-27 | |||
| 2023-09-30 | 77.73% 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | 77.73% 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 77.73% 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | 77.95% 10-K · filed 2024-02-27 | |||
| 2022-09-30 | 77.95% 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | 77.95% 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | 77.95% 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | 76.60% 10-K · filed 2024-02-27 | |||
| 2021-09-30 | 76.60% 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 76.60% 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | 76.60% 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 85.19% 10-K · filed 2023-02-23 | |||
| 2020-09-30 | 85.19% 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | 85.19% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 85.28% 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | 99.36% 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 101.70% 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | 101.70% 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | 101.70% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 96.78% 10-K · filed 2021-02-25 | |||
| 2018-09-30 | 96.56% 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | 95.78% 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | 95.60% 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | 94.19% 10-K · filed 2020-02-25 | |||
| 2017-09-30 | 93.84% 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | 94.09% 10-Q · filed 2018-08-03 | |||
| 2017-03-31 | 95.20% 10-Q · filed 2018-05-08 | |||
| 2016-12-31 | 94.86% 10-K · filed 2019-03-18 | |||
| 2016-09-30 | 96.60% 10-Q · filed 2017-11-07 | |||
| 2016-06-30 | 96.90% 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | 99.97% 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | 93.90% 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |